Genmab A/S
GMAB
Rank in Stocks
#957
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in... Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
Share Price
$406.14
Market Cap
$24.97B
Change (1 day)
0.51%
Change (1 year)
33.29%
Country
DK
Trade Genmab A/S (GMAB)
Category
Healthcare
P/E ratio for Genmab A/S (GMAB)
P/E ratio as of 2026 TTM: 0
According to Genmab A/S latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Genmab A/S from 2026 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | - |
US
|
|
| -28.36 | - |
US
|
|
| -24.57 | - |
AU
|
|
| - | - |
CH
|
|
| 30.33 | - |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.